Retatrutide

At a glance

---

What is retatrutide?

Retatrutide is a synthetic peptide -- a 39-amino-acid chain -- that simultaneously activates three receptors for metabolic hormones: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon.^[5] This triple-receptor approach makes it a "triagonist" and distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GIP + GLP-1).

The compound is being developed by Eli Lilly and Company under the research code LY3437943. Preclinical and Phase 1 data were published in 2022, followed by two landmark Phase 2 trials in 2023 that generated significant attention: one showed up to 24.2% body weight loss in people with obesity, and another showed HbA1c below 6.5% in up to 82% of people with type 2 diabetes.^[1][2]

Retatrutide is structurally similar to tirzepatide -- both are built on a GIP backbone, both use Aib residues for DPP-4 resistance, and both use a fatty acid moiety for albumin binding. The critical difference is the addition of glucagon receptor agonism, which is believed to drive increased energy expenditure and liver fat reduction -- effects not seen with GLP-1 or GIP agonism alone.

---

How it works

In plain terms, retatrutide mimics three gut and metabolic hormones that your body naturally uses to regulate blood sugar, appetite, and energy balance. By activating all three pathways at once, it produces stronger effects on weight and metabolism than drugs that target only one or two.^[5]

Think of it as working on three channels simultaneously: one primarily affecting insulin response and fat metabolism (GIP), another primarily affecting appetite and glucose regulation (GLP-1), and a third promoting energy expenditure and liver fat breakdown (glucagon). The combination appears to produce more than the sum of its parts.

Detailed mechanism (for advanced readers)

Retatrutide is a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors:^[5]

GIP receptor agonism (highest potency):

• Full agonist at the GIP receptor -- this is the dominant receptor interaction (similar to tirzepatide)
• GIP signaling in adipose tissue promotes lipid storage regulation and improves insulin sensitivity
• GIP receptor activation in the brain may contribute to appetite suppression
• Retatrutide is more potent at the GIP receptor than at native GIP

GLP-1 receptor agonism:

• Glucose-dependent insulin secretion from pancreatic beta cells
• Glucagon suppression from alpha cells
• Delayed gastric emptying (contributes to satiety and GI side effects)
• Central appetite regulation via hypothalamic and brainstem GLP-1 receptors
• Lower potency at GLP-1R compared to native GLP-1

Glucagon receptor agonism (the key differentiator):

• Promotes hepatic lipid oxidation and reduces liver fat -- explains the dramatic MASLD results
• Increases energy expenditure through thermogenesis
• Mobilizes hepatic glycogen and fatty acids
• May contribute to greater overall weight loss beyond GIP/GLP-1 effects
• This is what distinguishes retatrutide from both semaglutide and tirzepatide

Structural modifications:

• Two Aib (alpha-aminoisobutyric acid) residues at positions 2 and 20 for DPP-4 resistance
• Alpha-methyl-L-leucine at position 13 for additional stability
• C20 fatty diacid moiety attached via Lys17 enables albumin binding
• Half-life of approximately 6 days enables once-weekly dosing

How it differs from tirzepatide: Tirzepatide activates GIP and GLP-1 receptors but has no glucagon receptor activity. Retatrutide adds glucagon receptor agonism, which drives increased energy expenditure and hepatic fat reduction. This may explain the ~5-8 percentage points of additional weight loss seen in cross-trial comparisons.^[7]

---

What the research says

Retatrutide has produced the highest weight loss numbers ever reported for a pharmaceutical agent -- up to 24.2% in Phase 2 and 28.3% at 12 mg in the pivotal Phase 3 TRIUMPH-1 trial (n=2,339), with nearly half of that group losing 30%-plus — comparable to bariatric surgery. Five Phase 3 trials have now read out and they agree with each other. But the evidence base is still maturing: four of the five are company press releases rather than published papers, no cardiovascular benefit has been demonstrated, and FDA review has not begun.

Research timeline

Retatrutide's development has moved rapidly from preclinical work to Phase 3 trials:

Human clinical trials

Retatrutide has been studied in Phase 2 trials with a combined enrollment of approximately 878 participants, plus five reported Phase 3 trials: TRIUMPH-1 (2,339 participants), TRIUMPH-2 (1,152), TRIUMPH-3 (1,946), TRIUMPH-4 (445), and TRANSCEND-T2D-1 (537):

Phase 2 program: Three trials -- obesity without T2D (NEJM), type 2 diabetes (Lancet), and MASLD/fatty liver disease (Nature Medicine) -- established dose-response relationships and a safety profile.^[1][2][3]

Phase 3 TRIUMPH program: A set of registrational trials studying obesity in different populations — general obesity, obesity with type 2 diabetes, severe obesity with existing heart disease, and obesity with knee osteoarthritis. TRIUMPH-4 (knee OA) reported in December 2025; the pivotal TRIUMPH-1 (general obesity, n=2,339) reported topline results on May 21, 2026, with nested sleep-apnea and knee-OA basket data presented at ADA 2026; TRIUMPH-2 and TRIUMPH-3 reported topline on July 23, 2026.^{[6][4][10][13]}

Phase 3 TRANSCEND program: Evaluates retatrutide specifically for type 2 diabetes. TRANSCEND-T2D-1 (n=537) reported topline in March 2026 and was published in The Lancet on June 6, 2026 — the first peer-reviewed Phase 3 RCT for retatrutide — showing A1C reductions up to 1.94% and 15.3% weight loss as monotherapy.^[9]

Nested basket sub-studies within TRIUMPH-1 (ADA 2026)

Beyond the main obesity cohort, TRIUMPH-1 embedded two "basket" sub-studies that produced the first reported retatrutide efficacy data for sleep apnea and the largest knee-OA dataset to date.^[10]

• Obstructive sleep apnea (n=243, moderate-to-severe): Retatrutide reduced the apnea-hypopnea index (AHI) by up to 36.1 events/hour (60.6%) from a baseline of 58.6 events/hour. These remain the only reported retatrutide sleep-apnea efficacy data.
• Knee osteoarthritis (n=574): Retatrutide reduced WOMAC pain subscale scores by up to 4.3 points (a 73.1% placebo-adjusted reduction) from a baseline of 6.0 — consistent with the separate, dedicated TRIUMPH-4 knee-OA trial (n=445, reported December 2025). These are distinct studies and should not be conflated.

---

What the evidence shows

Retatrutide has generated enormous interest as a potential "next generation" weight loss drug. Here's what the published research tells us about the most common claims:

---

Safety & side effects

What clinical trials show

Retatrutide's safety profile is based on roughly 7,300 participants across Phase 2 and Phase 3 trials — including TRIUMPH-1 (n=2,339), TRIUMPH-3 (n=1,946), and TRIUMPH-2 (n=1,152). The overall profile is consistent with the GLP-1 receptor agonist class, with some notable additions.^[7]

Gastrointestinal events (the most common side effects): These are dose-dependent and typically most pronounced during dose escalation:

• Nausea: 38-43% at therapeutic doses (vs. ~10% placebo)
• Diarrhea: 33-35% (vs. ~13% placebo)
• Vomiting: 20-21% (vs. ~0% placebo)
• Constipation: 22-25% (vs. ~9% placebo)
• Decreased appetite: 18-19% (vs. ~9% placebo)

GI side effects were mostly mild-to-moderate, transient, and occurred primarily during dose escalation. The Phase 2 trial demonstrated that slower dose escalation (starting at 2 mg rather than 4 mg) partially mitigated GI events.^[1] TRANSCEND-T2D-1 showed lower GI rates at the highest dose (nausea 26.5%, diarrhea 22.8%, vomiting 17.6%), potentially reflecting optimized dose escalation in Phase 3.^[9]

Dysesthesia: dose-dependent but variable across trials

Urinary tract infections: now measured across three trials

TRIUMPH-1 surfaced a urinary tract infection (UTI) signal that had not appeared in the earlier retatrutide trials. UTIs were reported in 7.5% (4 mg), 8.8% (9 mg), and 8.4% (12 mg) of treated participants vs. 5.3% on placebo, and occurred predominantly in women. The infections were generally mild-to-moderate, mostly resolved during treatment, and rarely led to stopping the drug. A smaller, dose-dependent signal also appeared in TRANSCEND-T2D-1 (0.7%, 1.5%, and 2.9% across the 4/9/12 mg doses vs. 0% placebo). Investigators noted a possible link to hydration and said they will continue to monitor it as the program matures.^[12]

The July 2026 readouts give two more independent estimates, and they help put the signal in proportion. At the 12 mg dose, UTIs occurred in 8.0% vs. 6.6% on placebo in TRIUMPH-2 and 7.0% vs. 5.3% in TRIUMPH-3.^[13] Across three trials the excess over placebo is consistent — which suggests it is real — but small, on the order of 1 to 3 percentage points. In practical terms: UTIs are common in this population regardless of treatment, and retatrutide appears to add modestly to that background rate rather than introducing a new kind of risk. It is worth knowing about, particularly for women, and worth mentioning to a prescriber; it is not a reason for alarm on the evidence available.

Other safety concerns

• Heart rate increase: Resting heart rate increases of 5-10 beats per minute have been observed, peaking around week 24. This is a class effect shared with GLP-1 receptor agonists.
• Hypersensitivity reactions: Increased incidence reported in the meta-analysis. Serious hypersensitivity events were rare.
• Acute pancreatitis: Reported in trials, though no causal link confirmed. Consistent with GLP-1 class warnings.
• Lean mass loss: Expected with weight loss of this magnitude. Body composition data from Phase 2 sub-studies are being analyzed.
• Unknown long-term safety: The longest reported data is TRIUMPH-1's 104-week extension. There is no post-marketing surveillance data. Long-term risks, including thyroid C-cell tumor risk (a concern for the GLP-1 class), are not yet characterized.

Treatment discontinuation

In the Phase 2 obesity trial, treatment discontinuation due to adverse events was relatively low across all dose groups. In the pivotal TRIUMPH-1 trial, AE-related discontinuations rose with dose: 11.3% at 12 mg vs. 4.9% on placebo (4.1% at 4 mg, 6.9% at 9 mg). In TRIUMPH-4, the discontinuation rate was described as manageable despite the 20.9% dysesthesia rate at 12 mg. TRANSCEND-T2D-1 discontinuation rates were described as favorable compared to the tirzepatide Phase 3 program.^[10]

The 2026 readouts add useful range. TRIUMPH-2 had the lowest rate in the program — 7.7% at 12 mg vs. 4.9% on placebo — while TRIUMPH-3 had the highest, at 13.5% vs. 4.8%.^[13] That is worth reading carefully rather than averaging: TRIUMPH-3 enrolled people with severe obesity and established cardiovascular disease, the sickest group studied so far, and tested only the two highest doses (9 and 12 mg) rather than including a 4 mg arm. Roughly one in seven people at the top dose stopped because of side effects. Tolerability is not uniform, and it appears to depend on who is being treated.

What we don't know about safety

There are important gaps in the retatrutide safety data:

• No thyroid C-cell data in humans: GLP-1 receptor agonists carry a black box warning for thyroid C-cell tumors based on rodent studies. Retatrutide's risk has not been characterized.
• No long-term (>104 week) data: The longest reported trial data is TRIUMPH-1's 104-week extension. Chronic, multi-year use safety is unknown.
• No post-marketing surveillance: All data comes from controlled clinical trials. Real-world safety patterns may differ.
• Glucagon receptor concerns: The added glucagon receptor agonism is novel. Long-term effects of chronic glucagon stimulation on hepatic glucose production, bone health, and other systems are poorly understood.
• Dysesthesia mechanism unknown: Whether this is related to the glucagon receptor component, a dose-dependent drug effect, or an interaction remains unclear. The wide spread across trials at the same 12 mg dose — TRIUMPH-4 (20.9%), TRIUMPH-1 (12.5%), TRIUMPH-2 (7.3%), TRIUMPH-3 (6.4%), and TRANSCEND-T2D-1 (4.4%) — deepens this uncertainty.
• No cardiovascular outcomes result: TRIUMPH-3's exploratory MACE analysis was underpowered and pointed in both directions at once. The dedicated outcomes trial does not complete until 2029, so cardiovascular benefit — and cardiovascular safety at scale — is genuinely unknown.
• No pregnancy data: Animal reproductive toxicity is expected but not fully characterized.
• No drug interaction data: Formal drug interaction studies have not been published.

---

Legal & regulatory status

As of August 2026:

FDA status

Retatrutide is not FDA-approved for any indication. It is classified as an investigational drug undergoing Phase 3 clinical trials.

• No approved retatrutide product: FDA states retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition.^[11]
• No Fast Track or Breakthrough Therapy designation has been publicly announced, though the strength of Phase 2 data makes one or both designations plausible.
• A submission date, not an approval date: alongside the TRIUMPH-2 and TRIUMPH-3 results on July 23, 2026, Lilly said it plans to submit retatrutide to the FDA in the first quarter of 2027.^[13] That is company guidance about when the paperwork will be filed — nothing has been submitted yet.
• There is no PDUFA date. A PDUFA date is the deadline the FDA sets for itself once an application has been accepted for review. Because no application has been filed, no such date exists, and any source quoting one for retatrutide is guessing. Standard review takes about 10-12 months from filing; priority review can shorten that to roughly 6 months. On that arithmetic the earliest plausible approval is late 2027 into 2028, and timelines of this kind slip routinely.

How to access retatrutide today

For nearly everyone, the only route is enrollment in a clinical trial. The TRIUMPH and TRANSCEND programs have sites across multiple countries. Trial listings can be found at ClinicalTrials.gov by searching "retatrutide" or "LY3437943."^[6]

There is one other legitimate route, and it is narrow. Lilly has an open individual-patient expanded access program for retatrutide — sometimes called compassionate use — listed on ClinicalTrials.gov as available.^[15] It is intended for adults with a BMI of 35 or higher who also have two or more serious obesity-related complications, who have already failed maximum-dose approved therapy, and who cannot enroll in a retatrutide trial. A physician has to request it on a patient's behalf through the Lilly Answers Center; there is no way for a person to apply directly, and meeting the criteria does not guarantee access. It is worth knowing this exists — it is a real option that most coverage never mentions — while being clear that it is a route for a small number of people with severe, complicated obesity, not a workaround for the wait.

For the focused legal-status breakdown, see Retatrutide Is Not Compoundable.

WADA / USADA status

Retatrutide is not prohibited under the 2026 WADA Prohibited List. GLP-1 receptor agonists sit on WADA's Monitoring Program rather than the Prohibited List — semaglutide since 2024, with markers of semaglutide and tirzepatide monitored both in- and out-of-competition from 2026 — meaning their use by athletes is tracked but does not constitute an anti-doping violation. As a GLP-1-containing triple agonist, retatrutide is not currently prohibited, though WADA could move the class to the Prohibited List in a future update if evidence of performance-enhancing misuse emerges.^[8]

---

How retatrutide compares

Retatrutide's natural comparators are tirzepatide (dual agonist, same developer) and semaglutide (GLP-1 agonist, market leader). No head-to-head trials exist, so these comparisons rely on cross-trial data, which has important limitations:

The key tradeoffs:

• Weight loss: Retatrutide leads in cross-trial comparisons (28-30% in TRIUMPH-1 vs. tirzepatide 20-22% vs. semaglutide 13-17%). The pivotal TRIUMPH-1 trial showed 28.3% at 80 weeks, with 45.3% of the 12 mg group losing ≥30%; TRIUMPH-3 showed 22.6% and TRIUMPH-2 20.8% in harder-to-treat populations; TRANSCEND-T2D-1 showed 15.3% at 40 weeks in T2D. But no head-to-head trials exist.^{[10][4][9][13]}
• Liver fat reduction: Retatrutide leads decisively. The glucagon receptor component drives hepatic effects (82% reduction) not seen with GLP-1 or GIP/GLP-1 agonists.^[3]
• Cardiovascular protection: Semaglutide wins clearly. The SELECT trial (n=17,604) demonstrated a 20% reduction in MACE events. Tirzepatide has no completed outcomes trial, and neither does retatrutide — TRIUMPH-3's exploratory event counts were inconclusive, and TRIUMPH-Outcomes does not finish until 2029.
• Safety track record: Semaglutide and tirzepatide have years of post-marketing data from millions of patients. Retatrutide has data from roughly 7,300 trial participants. The dysesthesia signal varies by trial — TRIUMPH-4 (20.9%), TRIUMPH-1 (12.5%), TRIUMPH-2 (7.3%), TRIUMPH-3 (6.4%), TRANSCEND-T2D-1 (4.4%) at 12 mg — and remains worth monitoring.
• Availability: Semaglutide and tirzepatide are FDA-approved and available by prescription. Retatrutide is not available outside clinical trials.
• Oral option: Semaglutide has an oral formulation. Tirzepatide and retatrutide are injection-only.

The bottom line: retatrutide may eventually offer the strongest weight loss and metabolic benefits of the three, but it is years away from availability and has significantly less safety data. Semaglutide and tirzepatide are available now with robust evidence bases.

---

Related content

Guide

Retatrutide Is Not Compoundable

Focused legal-status guide explaining why retatrutide is trial-only and why research-use vendors are not equivalent to pharmacy access.

Peptide

Tirzepatide Profile

The dual GIP/GLP-1 agonist from Eli Lilly. FDA-approved for three indications. Retatrutide adds a third receptor (glucagon) to tirzepatide's dual mechanism.

Peptide

Semaglutide Profile

The GLP-1 agonist that pioneered the weight-loss peptide category. Retatrutide's cross-trial weight loss data substantially exceeds semaglutide.

Guide

What Are Peptides?

A foundational primer — helpful context for understanding retatrutide's triple-agonist mechanism.

News

TRANSCEND-T2D-1 Phase 3 Results

Breaking Phase 3 diabetes trial results — A1C reductions, weight loss data, and significantly lower dysesthesia rates than TRIUMPH-4.

News

Semaglutide Compounding Under Scrutiny

The regulatory landscape for GLP-1 agonists that shapes retatrutide's path to market.

Tool

Half-Life and Accumulation Plotter

Visualize how retatrutide's weekly dosing accumulates over time.

---

References

1. [1]

   Jastreboff AM, Kaplan LM, Frias JP, et al.. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023. 389(6):514-526 DOI PubMedRCT

   Landmark Phase 2 RCT. n=338. Up to 24.2% weight loss at 12 mg dose over 48 weeks. Weight loss curves not yet plateaued.

2. [2]

   Rosenstock J, Frias JP, Rodbard HW, et al.. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.” Lancet. 2023. 402(10401):529-544 DOI PubMedRCT

   Phase 2 RCT in T2D. n=281. HbA1c <6.5% in up to 82%. Active comparator (dulaglutide 1.5 mg).

3. [3]

   Sanyal AJ, Kaplan LM, Frias JP, et al.. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nat Med. 2024. 30(7):2037-2048 DOI PubMedRCT

   Phase 2a MASLD sub-study. n=98. Up to 82% liver fat reduction. 86% achieved normal liver fat at 12 mg. Glucagon receptor component may drive hepatic effects.

4. [4]

   Eli Lilly and Company. “Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.” 2025. LinkRCT

   Topline press release for TRIUMPH-4. n=445. 28.7% weight loss at 12 mg (68 weeks). Peer-reviewed publication pending. Dysesthesia signal at 20.9% (12 mg).

5. [5]

   Coskun T, Urva S, Roell WC, et al.. “LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Cell Metab. 2022. 34(9):1234-1247.e9 DOI PubMedAnimal study

   Key preclinical and Phase 1 paper from Eli Lilly discovery team. Establishes triple agonist receptor binding, preclinical pharmacology, and first-in-human PK/PD.

6. [6]

   Giblin MJ, Kaplan LM, Somers VK, et al.. “Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.” Diabetes Obes Metab. 2026. DOI PubMedReview

   Design rationale paper for TRIUMPH Phase 3 program. Describes novel basket trial design across obesity, OSA, and knee OA.

7. [7]

   Wang Y, Liu J, Zhang X, et al.. “Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.” Front Endocrinol. 2025.Systematic review

   Meta-analysis of 3 Phase 2 RCTs (n=878). Confirms dose-dependent weight loss and GI-dominant safety profile. Pre-dates Phase 3 data.

8. [8]

   World Anti-Doping Agency. “The 2026 Prohibited List — International Standard.” 2026. Link
9. [9]

   Bajaj HS, Frias JP, Rosenstock J, et al.. “Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.” Lancet. 2026. LinkRCT

   First peer-reviewed Phase 3 RCT for retatrutide (online June 6, 2026). n=537. Monotherapy vs. placebo. A1C reductions of 1.69%/1.86%/1.94% at 4/9/12 mg vs. 0.81% placebo (baseline 7.9%); 82-89% reached A1C <7.0%. Weight loss 15.3% at 12 mg in the Lancet analysis (the March 2026 topline press release reported 16.8% / 36.6 lb). Dysesthesia 2.3-4.5%.

10. [10]

    Eli Lilly and Company. “Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.” 2026. LinkRCT

    Topline press release (May 21, 2026) and ADA 2026 presentation for the pivotal TRIUMPH-1 obesity trial (NCT05929066). n=2,339, 80 weeks. Weight loss 28.3% (70.3 lb) at 12 mg, 25.9% (9 mg), 19.0% (4 mg) vs. 2.2% placebo; 45.3% lost ≥30% at 12 mg; 65.3% reached BMI <30; 104-week extension up to 30.3% (85.0 lb). Dysesthesia 12.5% at 12 mg; AE discontinuations 11.3% vs. 4.9% placebo. Nested baskets: OSA (n=243) AHI −36.1 events/hr (60.6%); knee OA (n=574) WOMAC pain −4.3 points (73.1%). Peer-reviewed publication pending.

11. [11]

    U.S. Food and Drug Administration. “FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” 2026. LinkSafety study

    FDA safety communication stating retatrutide cannot be used in compounding under federal law and warning about GLP-1 products falsely labeled for research purposes or not for human consumption.

12. [12]

    Eli Lilly and Company. “Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications.” 2026. LinkConference abstract

    Eli Lilly ADA 2026 topline release (June 6, 2026) for TRIUMPH-1; source for the new UTI safety signal and per-dose dysesthesia rates.

13. [13]

    Eli Lilly and Company. “Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C.” 2026. LinkRCT

    Company topline press release (July 23, 2026) reporting TRIUMPH-2 (NCT05929079, n=1,152, obesity + type 2 diabetes) and TRIUMPH-3 (NCT05882045, n=1,946 enrolled / 1,949 randomized, severe obesity + established cardiovascular disease), both at 80 weeks. Also the source for Lilly's stated plan to submit retatrutide to the FDA in Q1 2027. Neither trial has been peer-reviewed or presented at a conference. Accessed via a verbatim press-release mirror; the Lilly investor release is the underlying source.

14. [14]

    ClinicalTrials.gov. “NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes).” 2026. LinkRegistered trial (no results)

    Registry record for the dedicated retatrutide cardiovascular and kidney outcomes trial. Phase 3, approximately 10,000 participants, active and no longer recruiting, primary completion February 2029. A trial registration, not a result.

15. [15]

    ClinicalTrials.gov. “NCT07629401: Pre-approval Expanded Access of Retatrutide (LY3437943).” 2026. LinkRegistered trial (no results)

    Eli Lilly expanded access record, status 'available.' Individual-patient (single-patient) pre-approval access for adults with BMI ≥35 kg/m² plus two or more serious obesity-related complications who have failed maximum-dose approved therapy and cannot enroll in a retatrutide trial. Physician-initiated through the Lilly Answers Center. Not a clinical trial and not a consumer purchase route.

---